Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Re..Repurposed Drugs
View:
Post by Tarbaby on Jun 20, 2024 4:33pm

Re..Repurposed Drugs

Im still not sure if Rutherrin itself is FDA or Health Canada approved to go into a human.
Either alone or with another approved drug.
Does anyone know.??
Comment by Alamir1111 on Jun 20, 2024 4:59pm
Good question Tarbaby this is what internet showing Ruthenium compounds, such as ruthenium (IV) oxide, as considered highly toxic to humans and potential carcinogens (i.e., can cause the development of cancers). Radioisotopes of ruthenium, primarily Ru-106, are also dangerous to humans and exposure can increase one's risk of developing cancers.
Comment by Gooseybear on Jun 21, 2024 7:48am
Only Theralase management would come up with the name of their primary drug as compared to the one mentioned.
Comment by enriquesuave on Jun 21, 2024 10:49am
Fluorine gaz is deadly, yet we use fluoride in toothpaste everyday and it's safe.  Same difference between pure or radioactive isotope of Ruthenium vs Ruvidar or Rutherin.  A little chemical modification can render a poison into a life saving molecule.
Comment by Alamir1111 on Jun 21, 2024 12:58pm
Hi enriqesuave I also posted this. RE:RE:Re..Repurposed Drugs Did the news release mention Ruthenium  ?Ruvidar? There might be a sleight  difference between them
Comment by Tarbaby on Jun 21, 2024 1:47pm
COMPANY MUST CLARIFY THIS. I have not seen any .
Comment by Tarbaby on Jun 22, 2024 12:33am
I found an article regarding Ruthenium complexes that says they basicalky are safe. Its on Pubmed. I will truy to get it printed here or at least the contact info. At least tha takes me feel more confident.
Comment by CAinPlap on Jun 20, 2024 5:13pm
No its not. That's what we are wating for. Not expected until late 2026. 
Comment by Alamir1111 on Jun 20, 2024 5:33pm
Did the news release mention Ruthenium  ?Ruvidar? There might be a sleight  difference between them
Comment by DJDawg on Jun 20, 2024 6:02pm
The procedure is that they get HC approval to do a phase 1 trial. That has not happened yet.
Comment by Alamir1111 on Jun 20, 2024 6:47pm
Theralase® has demonstrated in preclinical research that Rutherrin® is able to accomplish this task with various drugs, by significantly enhancing their efficacy in the destruction of cancer cells and repurposing their use in the treatment of multiple cancer indications. Withaferin A, is a steroid primarily used as an anti-inflammatory drug to combat cancer-associated inflammation is ...more  
Comment by Alamir1111 on Jun 20, 2024 7:54pm
https://www.dovepress.com/withaferin-a-a-dietary-supplement-with-promising-potential-as-an-anti--peer-reviewed-fulltext-article-DDDT#t0001
Comment by Oilminerdeluxe on Jun 21, 2024 6:03am
Just a thought, might be a stupid one, but if Theralase really had a bigger player taking a few millions in the ongoing PP, wouldn't it be a good idea if they announced that in a PR now if they want even more money from shareholders? It would be easier to jump in if money is already guaranteed? Or maybe it is not allowed to do that way. Well, it was just a feeble thought. If they can get ...more  
Comment by Alamir1111 on Jun 21, 2024 7:02am
If they can raise close to 10 million $ that would be a huge confidence booster.
Comment by Gooseybear on Jun 21, 2024 7:59am
I think if Theralase brought in. New CEO from big pharma or the FDA you would see a share price explosion. The current management has credibility issues.
Comment by CAinPlap on Jun 21, 2024 9:56am
Its not a bad idea if we had the money to afford a new shiny CEO. Not sure we could offer a sufficient compensation package to entice recognized name in the industry. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250